Prostate Cancer Trial, Recruiting (NCT07516886)

Prostate Cancer Trial, Recruiting NCT07516886 Sponsor: Lithuanian University of Health Sciences Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07516886 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The person must be a biological adult male.
The person must have prostate cancer that has been confirmed through tissue examination and has not yet been treated.
The person must be scheduled to have their prostate removed through open surgery, keyhole surgery, or robot-assisted keyhole surgery.
The person must have been informed about the study and agreed to take part by signing a consent form.

Who may not be able to join:

People whose prostate cancer has been confirmed through scans or tissue examination to have spread to other parts of the body before surgery.
People who have already received treatment aimed at shrinking the prostate cancer before surgery.
People who are planned to receive additional treatment after surgery.
People who have any medical reasons that make the planned surgery unsafe for them.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daimantas Milonas, MD, PhD, Professor, Lietuvos sveikatos mokslų universitetas

Phone: +37063605330

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07516886

Sponsor: Lithuanian University of Health Sciences

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: +37063605330

More information: https://clinicaltrials.gov/study/NCT07516886

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The person must be a biological adult male.
The person must have prostate cancer that has been confirmed through tissue examination and has not yet been treated.
The person must be scheduled to have their prostate removed through open surgery, keyhole surgery, or robot-assisted keyhole surgery.
The person must have been informed about the study and agreed to take part by signing a consent form.

Who may not be able to join:

People whose prostate cancer has been confirmed through scans or tissue examination to have spread to other parts of the body before surgery.
People who have already received treatment aimed at shrinking the prostate cancer before surgery.
People who are planned to receive additional treatment after surgery.
People who have any medical reasons that make the planned surgery unsafe for them.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Lithuanian University of Health Sciences

Registry

ClinicalTrials.gov

Start date

22 January 2024

Est. completion

1 July 2039

Where this trial is recruiting

🇱🇹 Lithuania

Primary endpoints

Impact of PSA Persistence on Metastasis-Free Survival (MFS); Impact of PSA Persistence on Cancer-Specific Survival (CSS); Impact of PSA Persistence on Overall Survival (OS); Development of a Prognostic Nomogram Incorporating PSA Persistence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov